AMARIN CORP PLC\UK 10-Q

Item 5. Other Information None. 69 Item 6. Exhibits The following exhibits are incorporated by reference or filed or furnished as part of this report. Exhibit Number Description Incorporated by Reference Herein Form Date 10.1 Consent of Landlord to Sublease dated as of January 20, 2023, among Amarin Pharma, Inc. ST Shared Services LLC and Liberty Denver Wood LLC Annual Report on Form 10-K for the year ended December 31, 2022, as Exhibit 10.44 March 1, 2023 10.2 Guaranty dated January 20, 2023, issued by MEH, Inc. Annual Report on Form 10-K for the year ended December 31, 2022, as Exhibit 10.45 March 1, 2023 10.3 Sublease Agreement dated January 20, 2023, by and between Amarin Pharma, Inc. and ST Shared Services LLC Annual Report on Form 10-K for the year ended December 31, 2022, as Exhibit 10.46 March 1, 2023 31.1 Certification of Interim President and Chief Executive Officer (Interim Principal Executive Officer) pursuant to Section 302 of Sarbanes-Oxley Act of 2002 Filed herewith 31.2 Certification of Senior Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) pursuant to Section 302 of Sarbanes-Oxley Act of 2002 Filed herewith 32.1 Certification of Interim President and Chief Executive Officer (Interim Principal Executive Officer) and Senior Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) pursuant to Section 906 of Sarbanes-Oxley Act of 2002 Filed herewith 101.SCH Inline XBRL Taxonomy Extension Schema Document Filed herewith 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document Filed herewith 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document Filed herewith 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document Filed herewith 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document Filed herewith 104 Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*) Filed herewith 70 SIGNA TURE Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AMARIN CORPORATION PLC By: /s/ Aaron Berg Aaron Berg Interim President and Chief Executive Officer (Interim Principal Executive Officer) (On behalf of the Registrant) Date: May 3, 2023 AMARIN CORPORATION PLC By: /s/ Tom Reilly Tom Reilly Senior Vice President, Chief Financial Officer (Principal Financial and Accounting Officer) (On behalf of the Registrant) Date: May 3, 2023 71